MX2013008437A - Marcadores de formacion de imagen por resonancia magnetica, sistemas de suministro y extraccion, y metodos de fabricacion y uso de los mismos. - Google Patents

Marcadores de formacion de imagen por resonancia magnetica, sistemas de suministro y extraccion, y metodos de fabricacion y uso de los mismos.

Info

Publication number
MX2013008437A
MX2013008437A MX2013008437A MX2013008437A MX2013008437A MX 2013008437 A MX2013008437 A MX 2013008437A MX 2013008437 A MX2013008437 A MX 2013008437A MX 2013008437 A MX2013008437 A MX 2013008437A MX 2013008437 A MX2013008437 A MX 2013008437A
Authority
MX
Mexico
Prior art keywords
manufacture
delivery
methods
extraction systems
markers
Prior art date
Application number
MX2013008437A
Other languages
English (en)
Other versions
MX356514B (es
Inventor
Steven J Frank
Karen Martirosyan
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013008437A publication Critical patent/MX2013008437A/es
Publication of MX356514B publication Critical patent/MX356514B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1007—Arrangements or means for the introduction of sources into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N5/1039—Treatment planning systems using functional images, e.g. PET or MRI
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Se describen agentes de contraste y de formación de imagen a base de cobalto, no tóxicos y novedosos, para uso en modalidades mejoradas de formación de imagen médica, y procedimientos, así como la fabricación de marcadores que contienen a tales agentes de contraste, y usos para tales marcadores y agentes de contraste de formación de imagen en una variedad de aplicaciones y dispositivos terapéuticos.
MX2013008437A 2011-01-20 2012-01-20 Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos. MX356514B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434719P 2011-01-20 2011-01-20
PCT/US2012/022092 WO2012100206A2 (en) 2011-01-20 2012-01-20 Mri markers, delivery and extraction systems, and methods of manufacture and use thereof

Publications (2)

Publication Number Publication Date
MX2013008437A true MX2013008437A (es) 2013-12-06
MX356514B MX356514B (es) 2018-05-30

Family

ID=45563572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008437A MX356514B (es) 2011-01-20 2012-01-20 Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos.

Country Status (11)

Country Link
US (3) US8846006B2 (es)
EP (1) EP2665493B1 (es)
JP (1) JP5889337B2 (es)
CN (1) CN103442737B (es)
AU (1) AU2012207142B2 (es)
BR (1) BR112013018534B1 (es)
CA (1) CA2824521C (es)
IL (1) IL227576A (es)
MX (1) MX356514B (es)
WO (1) WO2012100206A2 (es)
ZA (1) ZA201304790B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350431B2 (en) 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
US9492683B2 (en) 2013-03-15 2016-11-15 Gammatile Llc Dosimetrically customizable brachytherapy carriers and methods thereof in the treatment of tumors
KR101458585B1 (ko) 2013-04-02 2014-11-07 연세대학교 산학협력단 심혈관 진단 및 치료영상의 실시간 정합을 위한 방사선 불투과성 반구형 표지
WO2015001372A1 (en) * 2013-07-03 2015-01-08 General Electric Company Method of contrast enhanced breast imaging, and contrast agent reference insert
US20160256714A1 (en) * 2013-10-01 2016-09-08 Empire Technology Development Llc Visualization of beam trajectories in radiation therapy
WO2016025786A1 (en) * 2014-08-15 2016-02-18 The Johns Hopkins University Post-surgical imaging marker
US11937909B2 (en) * 2014-10-27 2024-03-26 Sirius Medical Systems B.V. Magnetic marker, location detection system, introducer and method
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US9403033B1 (en) 2015-04-24 2016-08-02 Gammatile Llc Apparatus and method for loading radioactive seeds into carriers
WO2016179420A1 (en) 2015-05-06 2016-11-10 Gammatile Llc Radiation shielding
US11353533B2 (en) 2016-02-24 2022-06-07 Ohio State Innovation Foundation Methods and devices for contrast agent magnetic resonance imaging
US10751431B2 (en) 2016-06-23 2020-08-25 National Guard Health Affairs Positron emission capsule for image-guided proton therapy
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
US10016520B1 (en) * 2017-01-09 2018-07-10 SeeCure Taiwan Co., Ltd. Compound and pharmaceutical composition for tumor imaging and tumor therapy
US20180358221A1 (en) * 2017-06-07 2018-12-13 Macom Technology Solutions Holdings, Inc. Reduction of wafer bow during growth of epitaxial films
US11427801B2 (en) * 2017-11-09 2022-08-30 Case Western Reserve University Scatter labeled imaging of microvasculature in excised tissue (SLIME)
EP3717922A2 (en) 2017-12-03 2020-10-07 Cook Medical Technologies, LLC Mri compatible interventional wireguide
TWI684994B (zh) * 2018-06-22 2020-02-11 國立臺灣科技大學 脊椎影像註冊方法
US11737851B2 (en) 2018-06-28 2023-08-29 Cook Medical Technologies Llc Medical devices for magnetic resonance imaging and related methods
DE202018105883U1 (de) 2018-10-15 2018-11-02 Brainlab Ag Medizintechnischer Polymer-Marker
US10981018B2 (en) 2019-02-14 2021-04-20 Gt Medical Technologies, Inc. Radioactive seed loading apparatus
US11504546B2 (en) 2019-02-28 2022-11-22 Cowles Ventures, Llc Needle guidance device for brachytherapy and method of use
US11524176B2 (en) * 2019-03-14 2022-12-13 Cowles Ventures, Llc Locator for placement of fiducial support device method
KR102381029B1 (ko) * 2019-04-05 2022-03-31 연세대학교 산학협력단 대사체를 유효성분으로 포함하는 신규한 조영제 조성물
US10989774B2 (en) 2019-08-28 2021-04-27 Sigwa Company, Llc Retractable magnetic resonance imaging (MRI) magnet field assembly for an equine MRI system
CN113331276A (zh) * 2021-04-30 2021-09-03 贵州省雷山县毛克翕茶业有限公司 银球茶的制备方法
WO2023077375A1 (en) * 2021-11-04 2023-05-11 Shenzhen Xpectvision Technology Co., Ltd. In vivo xrf agent
NL2030157B1 (en) * 2021-12-16 2023-06-28 Nucletron Operations Bv Marking arrangement, medical device, and system for reconstructing a planned trajectory
CN116643049B (zh) * 2023-07-27 2023-09-29 云南省农业科学院质量标准与检测技术研究所 基于改性纳米金材料的丙溴磷农药胶体金标记物及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167564A (en) 1974-09-23 1979-09-11 Albion Laboratories, Inc. Biological assimilation of metals
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5422096A (en) * 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
ATE170753T1 (de) 1989-07-07 1998-09-15 Endorecherche Inc Androgenderivate zur hemming der aktivität der sexualsteroide
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5342283A (en) 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5575794A (en) 1993-02-12 1996-11-19 Walus; Richard L. Tool for implanting a fiducial marker
AU1439595A (en) 1993-12-22 1995-07-10 Salk Institute For Biological Studies, The Methods for reducing multidrug resistance
US6333971B2 (en) 1995-06-07 2001-12-25 George S. Allen Fiducial marker
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
US5713828A (en) 1995-11-27 1998-02-03 International Brachytherapy S.A Hollow-tube brachytherapy device
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DK0918774T3 (da) 1996-06-27 2002-05-21 Ligand Pharm Inc Androgenreceptormodulatorforbindelser og fremgangsmåder
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU722089B2 (en) 1996-12-13 2000-07-20 Chugai Seiyaku Kabushiki Kaisha Novel benzopyran derivatives
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CN1544436A (zh) 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� 3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002224A1 (en) 1997-07-07 1999-01-21 Lewis Robert D Statistical analysis and feedback system for sports employing a projectile
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
US5911885A (en) 1997-07-29 1999-06-15 Owens; Thomas L. Application of microwave radiation in a centrifuge for the separation of emulsions and dispersions
US6077880A (en) 1997-08-08 2000-06-20 Cordis Corporation Highly radiopaque polyolefins and method for making the same
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2311929A1 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
JP3568386B2 (ja) 1998-03-19 2004-09-22 富士通テン株式会社 ノイズキャンセラー回路
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
JP3419308B2 (ja) 1998-05-29 2003-06-23 トヨタ自動車株式会社 エンボス模様付き金属微細片の製造方法
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
US6261606B1 (en) * 1999-09-14 2001-07-17 Natural Compounds, Ltd. Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions
US7579338B2 (en) 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US6575888B2 (en) 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
GB0012487D0 (en) * 2000-05-24 2000-07-12 Pfylori Limited Use of metal compounds to treat gastrointestinal infections
US6534039B2 (en) 2000-07-21 2003-03-18 James F. Hainfeld Extended organic cobalt and nickel magnetic complexes
US6521773B1 (en) 2000-07-21 2003-02-18 James F. Hainfeld Extended organic cobalt and nickel magnetic complexes
US7776310B2 (en) 2000-11-16 2010-08-17 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US6514193B2 (en) 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
US7022086B2 (en) 2002-05-21 2006-04-04 Scimed Life Systems, Inc. Guidewire with encapsulated marker
KR100439962B1 (ko) * 2002-06-05 2004-07-12 한국원자력연구소 방사성 의약품용 테크네튬 또는 레늄 착물의 제조방법
US6957098B1 (en) 2002-06-27 2005-10-18 Advanced Cardiovascular Systems, Inc. Markers for interventional devices in magnetic resonant image (MRI) systems
US7014773B2 (en) 2003-02-21 2006-03-21 Exxonmobil Research And Engineering Company Demulsification of emulsions by socillatory mixing
US20050107870A1 (en) 2003-04-08 2005-05-19 Xingwu Wang Medical device with multiple coating layers
US7761138B2 (en) 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
CA2575649C (en) 2006-01-25 2015-04-14 University Of Victoria Innovation And Development Corporation Lanthanide rich nanoparticles, and their investigative uses in mri and related technologies
CN101827631B (zh) 2007-07-11 2013-04-24 得克萨斯系统大学董事会 用于成像中的粒子和标记物
CN101814352B (zh) * 2010-03-09 2012-05-30 上海师范大学 一种水溶性岩石盐型CoO纳米花状磁性粒子及其应用

Also Published As

Publication number Publication date
JP5889337B2 (ja) 2016-03-22
AU2012207142B2 (en) 2017-04-27
US20150017102A1 (en) 2015-01-15
BR112013018534A2 (pt) 2017-08-01
WO2012100206A3 (en) 2012-10-04
ZA201304790B (en) 2014-12-23
CA2824521C (en) 2016-06-28
IL227576A0 (en) 2013-09-30
JP2014504603A (ja) 2014-02-24
EP2665493B1 (en) 2018-03-21
CN103442737B (zh) 2017-03-29
IL227576A (en) 2016-07-31
EP2665493A2 (en) 2013-11-27
MX356514B (es) 2018-05-30
US9345790B2 (en) 2016-05-24
CN103442737A (zh) 2013-12-11
US9555135B2 (en) 2017-01-31
WO2012100206A2 (en) 2012-07-26
US8846006B2 (en) 2014-09-30
CA2824521A1 (en) 2012-07-26
BR112013018534B1 (pt) 2021-04-06
US20160136305A1 (en) 2016-05-19
US20120189551A1 (en) 2012-07-26
AU2012207142A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
MX2013008437A (es) Marcadores de formacion de imagen por resonancia magnetica, sistemas de suministro y extraccion, y metodos de fabricacion y uso de los mismos.
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
PH12015500115A1 (en) Glucagon analogues
IL239557B (en) Microarray for providing therapeutic material and methods for use
EP2811939A4 (en) METHOD AND USES OF BIOLOGICAL TISSUE FOR DIFFERENT STENTS AND OTHER MEDICAL APPLICATIONS
EP2595557A4 (en) COMBINED PROCESSING SYSTEMS, METHODS AND APPARATUS FOR BODY MODELING APPLICATIONS
EP2856421A4 (en) SYSTEMS AND METHODS FOR TRANSPARENT MEDICAL TREATMENT DELIVERY
IL237281B (en) Drug delivery systems and methods for treating bladder cancer comprising oxaliplatin
EP2750651A4 (en) SYSTEMS AND METHODS FOR ATTACHING MOBILE MEDICAL EQUIPMENT SUPPORT SYSTEMS TO PATIENT TRANSPORT DEVICES
EP2774596A4 (en) MEDICAL EXTENSION INSTRUMENT AND SET OF MEDICAL EXTENSION INSTRUMENTS
EP2854869A4 (en) BIOMATERIALS FOR USE AS DRUG-EXHAUSTIVE, MRI-DETECTABLE IMPLANTS FOR VASCULATION
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
WO2013166430A3 (en) Delivery of gaseous imaging contrast agent
EP2568990A4 (en) METHOD OF PRODUCING PLEURODESIS
MY158112A (en) Use of agomelatine in obtaining medicaments intended for the treatment of obsessive-compulsive disorder (ocd)
NZ719745A (en) Soluble fc gamma receptor for treatment of autoimmune bullous diseases
PH12015500306A1 (en) Arry-520 for use in treating cancer in a patient with low aag
EP2742956A4 (en) MEDICAMENT FOR MEDICAL APPLICATIONS AND METHODS FOR SEARCHING FOR NEW MEDICINAL PRODUCTS
ZA201300184B (en) Charged particle treatment,rapid patient positioning and method of use thereof
UA65038U (ru) Способ лечения больных послеродовыми психозами
UA100317C2 (uk) Спосіб визначення фізіологічного стану організму людини
AU2013902690A0 (en) Improvements in medical treatment involving a magnetic field
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
UA53217U (en) Mask for therapy and general health improvement

Legal Events

Date Code Title Description
FG Grant or registration